Graves' orbitopathy

Tocilizumab Shows Promising Benefits in Glucocorticoid-Resistant Thyroid Eye Disease

In two prospective cohorts of active, glucocorticoid-resistant thyroid eye disease, tocilizumab improved eye inflammation, proptosis, diplopia, and quality of life with acceptable safety, supporting IL-6 blockade as a promising second-line